Therapeutic uses of inhibitors of RTP801
AssigneesQuark Pharmaceuticals, Inc., Silence Therapeutics GmbH
InventorElena Feinstein
Life of this patent
Estimating the term…
Abstract
The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of the RTP801 gene and/or protein.
Claims28
A method of treating a patient suffering from a respiratory disorder, an eye disease, a microvascular disorder, or a spinal cord injury or disease which comprises administering to the patient a pharmaceutical composition comprising an RTP801 inhibitor in an amount effective to treat the patient.
A method for treating a patient suffering from a respiratory disorder, an eye disease, a microvascular disorder or a spinal cord injury or disease which comprises administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of a polynucleotide RTP801 inhibitor so as to thereby treat the patient.
Use of a therapeutically effective amount of an RTP801 inhibitor for the preparation of a medicament for promoting recovery in a patient suffering from a respiratory disorder, an eye disease, a microvascular disorder or spinal cord injury or disease.
Dependencies are inferred from the claim text.